Philip Schoenfeld, MD
John D. Dingell VA Medical Center
Detroit, MI

He completed his Medical Degree and Master’s Degree in Medical Education at the University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, and completed his Master’s Degree in Clinical Epidemiology at McMaster University School of Medicine, Hamilton, Ontario. He completed his internal medicine residency at Naval Medical Center, Portsmouth, Virginia and completed his gastroenterology fellowship at National Naval Medical Center, Bethesda, Maryland, where he served as Chief of Gastroenterology Research from 1995-2000. He resigned his commission in the US Navy in 2000 with the rank of Commander.

Currently, Dr. Schoenfeld is Section Editor of the Selected Summaries section of the journal Gastroenterology. He is past Associate Editor (Colon) for the American Journal of Gastroenterology and past Associate Editor of Evidence Based Gastroenterology. He has served on the Editorial Boards for the Journal of Clinical Gastroenterology, Gastroenterology & Hepatology, Evidence Based Gastroenterology, and Alimentary Pharmacology and Therapeutics. He is a past member of the Governing Board of the American Gastroenterological Association and past Chair of the AGA’s Education Committee. Currently, he is Chair of the AGA’s Clinical Practice Section.

Dr. Schoenfeld’s research focuses on efficacy of colorectal cancer screening tools, irritable bowel syndrome treatments, and the application of evidence based medicine concepts to clinical gastroenterology. He is the recipient of multiple National Institute of Health research grants in colorectal cancer screening and has published multiple outcomes research studies on IBS and review articles about evidence based medicine principles. His original research articles have been published in the New England Journal of Medicine, Annals of Internal Medicine, Gastroenterology, and American Journal of Gastroenterology. He has co-authored the American College of Gastroenterology Evidence Based Approach to the Management of Irritable Bowel Syndrome, the American College of Gastroenterology Evidence Based Approach to the Management of Chronic Constipation, and the 2008 ACG Guideline for CRC Screening.

 Safety and Tolerability Profile of Rifaximin for Treatment of IBS without Constipation: Results of a Pooled Analysis of Double-Blind, Placebo-Controlled Randomized Controlled Trials

 Impact of Concurrent Use of PPIs or Anti-depressants on Efficacy of Rifaximin for IBS without Constipation

 Efficacy of Rifaximin for IBS without Constipation in Men and Women

 Predictive Value of Adequate Relief of Global IBS Symptoms During First Two Weeks of Rifaximin Use on Subsequent Relief of Daily IBS Symptoms and Daily Bloating Symptoms

 Prevalence and Topography of Adenomas in 40-49 Year Old Patients With a Family History of Colon Cancer

Conflicting guideline recommendations for screening colonoscopy result due to scant data upon which to develop appropriate recommendations. No previous study has compared the prevalence of advanced adenomas or adenomas (any size) among 40-49 year old individuals with a first degree relative (FDR) with colorectal cancer (CRC) versus 40-49 year old average risk individuals with no family history of CRC. The purpose of this study is to determine the prevalence of colon adenomas in 40-49 year old individuals and identify risk factors associated with the presence of advanced adenomas. This data will provide evidence to determine appropriate colon cancer screening guidelines in 40-49 year old persons with a family history of colon polyps or colorectal cancer.

Estimated Enrollment: 2910
Study Start Date: April 2006
Estimated Study Completion Date: June 2015
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)

 Diabetes and Periodontal Therapy Trial

The primary aim of the study is to determine if non-surgical periodontal therapy (scaling and root planing and supportive periodontal therapy) is efficacious compared to delayed therapy in reducing elevated glycosylated hemoglobin (HbA1c) at 6 months post-randomization in subjects with type 2 diabetes and untreated, moderate to advanced chronic periodontitis.

Estimated Enrollment: 600
Study Start Date: October 2009
Estimated Study Completion Date: June 2013
Estimated Primary Completion Date: June 2013 (Final data collection date for primary outcome measure

 Observation, Combination Chemotherapy, Radiation Therapy, and/or Autologous Stem Cell Transplant in Treating Young Patients With Neuroblastoma

Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving combination chemotherapy may kill more tumor cells. Radiation therapy uses high-energy x-rays to kill tumor cells. An autologous stem cell transplant may be able to replace blood-forming cells that were destroyed by chemotherapy and radiation therapy. This may allow more chemotherapy to be given so that more tumor cells are killed. Sometimes, after surgery, the tumor may not need more treatment until it progresses. In this case, observation may be sufficient. It is not yet known whether observation is more effective than combination chemotherapy, radiation therapy, and/or autologous stem cell transplant in treating neuroblastoma.

PURPOSE: This randomized phase III and phase IV trial is studying observation, combination chemotherapy, radiation therapy, and/or autologous stem cell transplant to compare how well they work in treating young patients with neuroblastoma.

Estimated Enrollment: 642
Study Start Date: October 2004
Estimated Completion Date: December 2010

 Rituximab in Treating Young Patients Who Are Receiving Chemotherapy for B-Cell Non-Hodgkin's Lymphoma or B-Cell Acute Lymphoblastic Leukemia

Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them. Others interfere with the ability of cancer cells to grow and spread. Giving rituximab before chemotherapy may be an effective treatment for B-cell non-Hodgkin's lymphoma or B-cell acute lymphoblastic leukemia.

This phase II trial is studying how well rituximab works in treating young patients who are planning to receive chemotherapy for B-cell non-Hodgkin's lymphoma or B-cell acute lymphoblastic leukemia.

Estimated Enrollment: 79
Study Start Date: March 2004

 Dissection of Staphylococcus Aureus Infection From Colonization in Cystic Fibrosis Patients

Staphylococcus aureus is not only one of the first pathogens infecting the airways of cystic fibrosis (CF) patients, but also a highly prevalent microorganism (>60% of all CF patients; European and American CF registries; (4,25), which often persists for several years in the respiratory tract of CF patients.

The purpose of this study is to dissect infection by S. aureus from colonization. Therefore, the following non-interventional prospective, longitudinal multicenter study will be conducted to develop the following hypothesis: CF patients with high bacterial loads are more likely to be infected by S. aureus than patients with low bacterial loads.

Estimated Enrollment: 248
Study Start Date: July 2008
Estimated Completion Date: December 2010
Estimated Primary Completion Date: June 2010

 Novel Influenza A (H1N1) Surveillance Registry

The demographic characteristics, clinical features, course, and outcomes of severe H1N1 influenza infection requiring intensive care have not been defined rigorously and systematically. While the majority of patients in early reports of critically ill novel influenza A (H1N1) have respiratory involvement, up to 10-20% may present with non-respiratory organ failures, such as shock, seizures, or acute renal failure. The burden of disease and resource utilization of these patients remains largely unknown. The purpose of this surveillance registry is to characterize the demographics, clinical features, outcomes, and resource utilization of patients with H1N1 influenza infection who require intensive care.

Estimated Enrollment: 2000
Study Start Date: October 2009

 Early Versus Delayed Enteral Feeding to Treat People With Acute Lung Injury or Acute Respiratory Distress Syndrome (The EDEN Study)

Acute respiratory distress syndrome (ARDS) and acute lung injury (ALI) are medical conditions that occur when there is severe inflammation and increased fluids in both lungs, making it difficult for the lungs to function properly. Hospital treatment for a person with ALI/ARDS often includes the use of a breathing machine, or ventilator, until the person is able to breathe without assistance. Initiating proper nutrition through a feeding tube early in a person's hospital stay may help to improve recovery, but the optimal timing, composition, and amount of feeding treatments remain unknown. This study will evaluate whether early or delayed full-calorie feeding through a feeding tube is more effective in reducing recovery time and increasing survival rates in people with ALI/ARDS.

Estimated Enrollment: 1000
Study Start Date: December 2007
Estimated Study Date Completion: May 2011
Estimated Primary Completion Date: May 2011

 Improving Treatment Outcomes in Pharmacotherapy of Generalized Social Anxiety Disorder

This study will compare the effectiveness of either adding clonazepam or placebo to standard treatment or switching to venlafaxine in treating generalized social anxiety disorder in individuals who have not responded to treatment with sertraline.

Estimated Enrollment: 490
Study Start Date: March 2006
Estimated Study Completion Date: May 2011
Estimated Primary Completion Date: May 2011


    IBS Headlines 2022

    Gregory Sayuk, MD, MPH

    Didactic Lecture

    view details >


    Up-To-Date Diagnosis and Management of IBS and chronic Constipation in Primary Care

    view details >

    Understanding and Managing IBS and CIC in the primary care setting

    view details >

    An Evidence-Based Approach to IBS and CIC: Applying New Advances to Daily Practice

    view details >

    Advances in IBS

    view details >

    IBS News Tonight

    view details >

    Gastroparesis: Diagnosis and Management

    view details >

    Managing the Gastrointestinal Effects of Opioids

    view details >

    Implementing Effective Patient Communication Skills in IBS

    view details >


    IBS Headlines 2022

    Gregory Sayuk, MD, MPH

    Didactic Lecture

    view details >

    Dinner Meetings

    Content available soon


    Content available soon!

    Content available soon!

    © Copyright 2013-2023 GI Health Foundation. All rights reserved.
    This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.